1. Pulmonary Hypertension Updates From 2018

2. Diagnosis of PAH

3. PAH Hemodynamic Definitions Have Changed Over Time

4. Exploring the New Hemodynamic Definition

5. Borderline mPAP (21 to 24 mmHg) is Associated With Increased Risk of PAH

6. New Definitions, More Patients Will Benefit

7. Risk Assessment and Classification of PAH

8. Clinical Classification of PH

9. Updated Clinical Classification of PH

10. Genetics and Genomics of PAH

11. PAH Risk Stratification

12. Achieving Low-Risk Status in PAH

13. Continuously Reassess and Get Patient to Goal

14. Registry Data Confirm Need for Early Diagnosis and Treatment Intensification

15. Treatment of PAH

16. 3 Pathobiological Pathways in PAH

17. Treatment Strategy is Based on Risk Stratification

18. Algorithm for Treatment-Naive PAH Patient

19. Candidates for Monotherapy

20. Algorithm for Patient After Initial Treatment

21. Recommendations for Treatment Escalation in Patient on Background ERA + PDE5I

22. Place of Lung Transplantation in PAH Management

23. PAH Updates

24. High Level of Awareness for PAH

25. Algorithm for Diagnosing PH

26. Echocardiographic Signs of PH

27. Expert Centers Diagnosis and Follow-Up With Multidisciplinary Teams

29. Initial Risk Assessment Determines Initial Treatment

30. PAH Treatment Continuum

31. Updates in CTEPH

32. Natural History of Chronic Thromboembolic Pulmonary Hypertension

33. Incidence of CTEPH After an Acute PE

34. CTEPH Management

35. PEA is the Treatment of Choice for Operable Patients With CTEPH

36. Balloon Pulmonary Angioplasty for Inoperable CTEPH[a]

37. CHEST-1 Riociguat for the Treatment of CTEPH

38. MERIT-1 (Phase 2 Double-Blind Study) Macitentan in 80 Patients With Inoperable CTEPH

39. Summary

40. Management of CTEPH

41. Abbreviations

42. Abbreviations (cont)

43. Abbreviations (cont)